SG11201701039PA - Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1 - Google Patents
Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1Info
- Publication number
- SG11201701039PA SG11201701039PA SG11201701039PA SG11201701039PA SG11201701039PA SG 11201701039P A SG11201701039P A SG 11201701039PA SG 11201701039P A SG11201701039P A SG 11201701039PA SG 11201701039P A SG11201701039P A SG 11201701039PA SG 11201701039P A SG11201701039P A SG 11201701039PA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- human
- combination therapy
- activating
- antibodies against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14181067 | 2014-08-14 | ||
| EP15159611.1A EP3070102A1 (en) | 2015-03-18 | 2015-03-18 | Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies |
| PCT/EP2015/068404 WO2016023875A1 (en) | 2014-08-14 | 2015-08-11 | Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701039PA true SG11201701039PA (en) | 2017-03-30 |
Family
ID=53800992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701039PA SG11201701039PA (en) | 2014-08-14 | 2015-08-11 | Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20160045597A1 (en) |
| EP (2) | EP3626740A1 (en) |
| JP (1) | JP6586454B2 (en) |
| KR (1) | KR20170035945A (en) |
| CN (1) | CN106659780A (en) |
| AU (1) | AU2015303239A1 (en) |
| BR (1) | BR112016029334A2 (en) |
| CA (1) | CA2949739A1 (en) |
| IL (1) | IL249189A0 (en) |
| MX (1) | MX2017001976A (en) |
| RU (1) | RU2017108173A (en) |
| SG (1) | SG11201701039PA (en) |
| TW (1) | TW201609141A (en) |
| WO (1) | WO2016023875A1 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114835812A (en) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | anti-PD-L1 antibodies and their use for enhancing T cell function |
| EP3268392A2 (en) | 2015-03-13 | 2018-01-17 | CytomX Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| PL3400246T3 (en) | 2016-01-08 | 2021-03-08 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
| ES2924775T3 (en) | 2016-01-28 | 2022-10-10 | Inst Nat Sante Rech Med | Methods and pharmaceutical composition for the treatment of cancer |
| KR102531889B1 (en) | 2016-06-20 | 2023-05-17 | 키맵 리미티드 | Anti-PD-L1 and IL-2 cytokines |
| CN110402255B (en) * | 2017-04-04 | 2022-12-02 | 豪夫迈·罗氏有限公司 | Novel bispecific antigen binding molecules capable of specifically binding to CD40 and FAP |
| AU2018250875A1 (en) * | 2017-04-13 | 2019-10-03 | F. Hoffmann-La Roche Ag | An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer |
| AU2018278327B2 (en) | 2017-06-01 | 2023-03-16 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies and methods of use thereof |
| US11142580B2 (en) * | 2017-06-01 | 2021-10-12 | Psioxus Therapeutics Limited | Oncolytic virus and method |
| EP3768316A4 (en) * | 2018-03-23 | 2022-06-01 | The University Of Western Australia | Method for immunotherapy drug treatment |
| US20210147547A1 (en) * | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| CN112638375A (en) | 2018-06-15 | 2021-04-09 | 旗舰创业创新五公司 | Increasing immune activity through modulation of post-cellular signaling factors |
| AU2019379576A1 (en) | 2018-11-13 | 2021-06-03 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| AR117091A1 (en) * | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | MONOCLONAL ANTIBODIES ANTAGONISTS AGAINST CD40 AND THEIR USES |
| US20220089758A1 (en) * | 2019-01-22 | 2022-03-24 | Revmab Biosciences Usa, Inc. | Novel anti-cd40 antibodies |
| MA55805A (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | METHODS OF MODULATING IMMUNE ACTIVITY |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| JP2024503654A (en) | 2021-01-13 | 2024-01-26 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | combination therapy |
| AU2022246895A1 (en) | 2021-03-31 | 2023-10-19 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (en) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | CHANGED ANTIBODIES. |
| AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| ES2437327T3 (en) * | 2007-06-18 | 2014-01-10 | Merck Sharp & Dohme B.V. | Antibodies for the human programmed PD-1 receptor of programmed death |
| CN114835812A (en) * | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | anti-PD-L1 antibodies and their use for enhancing T cell function |
| BR112014002353B1 (en) * | 2011-08-01 | 2022-09-27 | Genentech, Inc | USES OF PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND KIT |
| WO2013043569A1 (en) * | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
-
2015
- 2015-08-11 AU AU2015303239A patent/AU2015303239A1/en not_active Abandoned
- 2015-08-11 CN CN201580036567.7A patent/CN106659780A/en active Pending
- 2015-08-11 EP EP19177793.7A patent/EP3626740A1/en not_active Withdrawn
- 2015-08-11 SG SG11201701039PA patent/SG11201701039PA/en unknown
- 2015-08-11 EP EP15748249.8A patent/EP3180357B1/en not_active Not-in-force
- 2015-08-11 JP JP2017507983A patent/JP6586454B2/en not_active Expired - Fee Related
- 2015-08-11 CA CA2949739A patent/CA2949739A1/en not_active Abandoned
- 2015-08-11 WO PCT/EP2015/068404 patent/WO2016023875A1/en active Application Filing
- 2015-08-11 KR KR1020177003938A patent/KR20170035945A/en not_active Application Discontinuation
- 2015-08-11 MX MX2017001976A patent/MX2017001976A/en unknown
- 2015-08-11 BR BR112016029334A patent/BR112016029334A2/en not_active Application Discontinuation
- 2015-08-11 RU RU2017108173A patent/RU2017108173A/en not_active Application Discontinuation
- 2015-08-13 TW TW104126436A patent/TW201609141A/en unknown
- 2015-08-14 US US14/827,044 patent/US20160045597A1/en not_active Abandoned
-
2016
- 2016-11-24 IL IL249189A patent/IL249189A0/en unknown
-
2017
- 2017-10-02 US US15/722,585 patent/US20180051077A1/en not_active Abandoned
-
2019
- 2019-12-11 US US16/710,188 patent/US20200095313A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170035945A (en) | 2017-03-31 |
| JP6586454B2 (en) | 2019-10-02 |
| MX2017001976A (en) | 2017-08-02 |
| BR112016029334A2 (en) | 2018-01-09 |
| TW201609141A (en) | 2016-03-16 |
| US20180051077A1 (en) | 2018-02-22 |
| EP3180357B1 (en) | 2019-07-03 |
| US20200095313A1 (en) | 2020-03-26 |
| CN106659780A (en) | 2017-05-10 |
| US20160045597A1 (en) | 2016-02-18 |
| EP3180357A1 (en) | 2017-06-21 |
| AU2015303239A1 (en) | 2016-12-15 |
| JP2017529327A (en) | 2017-10-05 |
| RU2017108173A (en) | 2018-09-17 |
| RU2017108173A3 (en) | 2019-03-11 |
| EP3626740A1 (en) | 2020-03-25 |
| IL249189A0 (en) | 2017-01-31 |
| CA2949739A1 (en) | 2016-02-18 |
| WO2016023875A1 (en) | 2016-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249189A0 (en) | Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1 | |
| IL279001A (en) | Nasal drug products and methods of their use | |
| IL274568A (en) | Cot modulators and methods of use thereof | |
| HK1217021A1 (en) | Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1 csf-1r pd-l1 | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| EP3177199A4 (en) | Medical devices and methods of placement | |
| GB201418350D0 (en) | Dispenser and methods of use thereof | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| EP3183010A4 (en) | Devices for treating medical waste and methods of their use | |
| GB201404470D0 (en) | Therapeutic methods and materials | |
| IL265955A (en) | Therapeutic compounds and methods of use thereof | |
| EP3134108A4 (en) | Agents and methods of treatment | |
| EP3145573A4 (en) | Portable medical treatment system and method of use | |
| EP3154442A4 (en) | Tissue retractor and methods of use | |
| HK1258056A1 (en) | Therapeutic compounds and methods of use thereof | |
| IL251135A (en) | Method for the synthesis of hydroxy-triglycerides and use thereof for the prevention and treatment of diseases | |
| EP3119307A4 (en) | Skin treatment devices and methods | |
| GB201404610D0 (en) | Preparation and method for the treatment of skin | |
| AU2014901480A0 (en) | Agents and methods of treatment | |
| GB201410387D0 (en) | Compounds and their therapeutic use | |
| GB201403496D0 (en) | Compounds and their therapeutic use |